Eli Lilly Stock Rises on FDA Approval, Upgrade

The majority of analysts are leaning bullish toward LLY

Deputy Editor
Sep 22, 2022 at 10:03 AM
facebook twitter linkedin


Eli Lilly and Co (NYSE:LLY) is getting a boost today, after news that the U.S. Food & Drug Administration (FDA) approved its cancer drug Retevmo for new uses, including treatment of patients with a sub-group of advanced tumor. LLY received an upgrade today as well, with UBS upping its rating to "buy" from "neutral." The firm added a price-target hike to $363 from $335, praising the company's new weight-loss drug, Mounjaro. 

At last glance, LLY was up 2.2% to trade at $302.90. The stock yesterday pulled back to its lowest level in three months, though long-term support at the 160-day moving average prevented further losses. Year-to-date, the equity is up 7.3%. 

Today's upgrade has UBS joining an optimistic brokerage bunch, as 19 of the 25 in coverage now carry a "buy" or better rating. Plus, the 12-month consensus price target of $346.00 is a 16.7% premium to last night's close. 

 

 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners